Evidence map›Paper›PMID 29168350›Full record

ArticleMolecular genetics & genomic medicine2018

Breakpoint mapping and haplotype analysis of translocation t(1;12)(q43;q21.1) in two apparently independent families with vascular phenotypes.

Tiia Maria Luukkonen, Mana M Mehrjouy, Minna Pöyhönen, Anna-Kaisa Anttonen, Päivi Lahermo, Pekka Ellonen, Lars Paulin, Niels Tommerup, Aarno Palotie, Teppo Varilo

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Tiia Maria LuukkonenInstitute for molecular medicine Finland FIMM, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6430-6410
Mana M MehrjouyWilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Minna PöyhönenClinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Anna-Kaisa AnttonenLaboratory of Genetics, HUSLAB, Helsinki, Finland.
Päivi LahermoInstitute for molecular medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
Pekka EllonenInstitute for molecular medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
Lars PaulinInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Niels TommerupWilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Aarno PalotieInstitute for molecular medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
Teppo VariloDepartment of Health, National Institute for Health and Welfare, Helsinki, Finland.
University of Helsinki · FIUniversity of Copenhagen · DKBroad Institute · USHospital District of Helsinki and Uusimaa · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk of serious congenital anomaly for de novo balanced translocations is estimated to be at least 6%. We identified two apparently independent families with a balanced t(1;12)(q43;q21.1) as an outcome of a "Systematic Survey of Balanced Chromosomal Rearrangements in Finns." In the first family, carriers (n = 6) manifest with learning problems in childhood, and later with unexplained neurological symptoms (chronic headache, balance problems, tremor, fatigue) and cerebral infarctions in their 50s. In the second family, two carriers suffer from tetralogy of Fallot, one from transient ischemic attack and one from migraine. The translocation cosegregates with these vascular phenotypes and neurological symptoms. METHODS AND

resultsWe narrowed down the breakpoint regions using mate pair sequencing. We observed conserved haplotypes around the breakpoints, pointing out that this translocation has arisen only once. The chromosome 1 breakpoint truncates a CHRM3 processed transcript, and is flanked by the 5' end of CHRM3 and the 3' end of RYR2. TRHDE, KCNC2, and ATXN7L3B flank the chromosome 12 breakpoint.

conclusionsThis study demonstrates a balanced t(1;12)(q43;q21.1) with conserved haplotypes on the derived chromosomes. The translocation seems to result in vascular phenotype, with or without neurological symptoms, in at least two families. We suggest that the translocation influences the positional expression of CHRM3, RYR2, TRHDE, KCNC2, and/or ATXN7L3B.

Indexed as

AdultAgedBase SequenceChromosome AberrationsChromosome BreakpointsChromosome MappingChromosomes, Human, Pair 1Chromosomes, Human, Pair 12FemaleFinlandHaplotypesHeterozygoteHumansKaryotypingMaleMiddle AgedATXN7L3B protein, humanCHRM3 protein, humanKCNC2 protein, humanReceptor, Muscarinic M3Ryanodine Receptor Calcium Release ChannelRyR2 protein, humanShaw Potassium ChannelsTranscription Factorsbalanced translocationconserved haplotypesmate pair sequencingposition effectvascular phenotypes

Identifiers

PMID29168350
PMCPMC5823676
OpenAlexW2770320704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.